1. Home
  2. OFG vs COGT Comparison

OFG vs COGT Comparison

Compare OFG & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OFG Bancorp

OFG

OFG Bancorp

HOLD

Current Price

$42.35

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$41.02

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OFG
COGT
Founded
1964
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
6.5B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
OFG
COGT
Price
$42.35
$41.02
Analyst Decision
Buy
Buy
Analyst Count
4
13
Target Price
$45.75
$28.08
AVG Volume (30 Days)
241.8K
3.1M
Earning Date
01-21-2026
11-03-2025
Dividend Yield
2.84%
N/A
EPS Growth
6.55
N/A
EPS
4.40
N/A
Revenue
$624,004,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.09
N/A
P/E Ratio
$9.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$33.15
$3.72
52 Week High
$46.11
$43.73

Technical Indicators

Market Signals
Indicator
OFG
COGT
Relative Strength Index (RSI) 65.53 68.51
Support Level $41.57 $37.86
Resistance Level $42.44 $43.73
Average True Range (ATR) 0.70 2.12
MACD 0.30 -0.57
Stochastic Oscillator 89.81 46.08

Price Performance

Historical Comparison
OFG
COGT

About OFG OFG Bancorp

OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. The company derives maximum revenue from Banking Segment. It provides services in the region of Puerto Rico.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: